The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
The diagnosis and management of malignant phaeochromocytoma and paraganglioma
Abstract
Malignant phaeochromocytomas are rare tumours accounting for ~10% of all phaeochromocytomas; the prevalence of malignancy among paragangliomas is higher, especially those associated with succinate dehydrogenase subunit B gene mutations. Although a subset of these tumours has metastatic disease at initial presentation, a significant number develops metastases during follow-up after excision of an apparently benign tumour. Clinical, biochemical and histological features cannot reliably distinguish malignant from benign tumours. Although a number of recently introduced molecular markers have been explored, their clinical significance remains to be elucidated from further studies. Several imaging modalities have been utilised for the diagnosis and staging of these tumours. Functional imaging using radiolabelled metaiodobenzylguanidine (MIBG) and more recently, 18 F-fluorodopamine and 18 F-fluorodopa positron emission tomography offer substantial sensitivity and specificity to correctly detect metastatic phaeochromocytoma and paraganglioma and helps identify patients suitable for treatment with radiopharmaceuticals. The 5-year mortality rate of patients with malignant phaeochromocytomas and paragangliomas greater than 50% indicates that there is considerable room for the improvement of currently available therapies. The main therapeutic target is tumour reduction and control of symptoms of excessive catecholamine secretion. Currently, the best adjunctive therapy to surgery is treatment with radiopharmaceuticals using 131 I-MIBG; however, this is very rarely curative. Chemotherapy has been used for metastatic disease with only a partial and mainly palliative effect. The role of other forms of radionuclide treatment either alone or in combination with chemotherapy is currently evolving. Ongoing microarray studies may provide novel intracellular pathways of importance for proliferation/cell cycle control, and lead to the development of novel pharmacological agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pheochromocytoma: recommendations for clinical practice from the First International Symposium
Pacak, K., Eisenhofer, G., Ahlman, H., Bornstein, S. R., Gimenez-Roqueplo, A.-P., Grossman, A. B., Kimura, N., Mannelli, M., McNicol, A. M., & Tischler, A. S. (2007) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0396 · Cited by 680
Self-citationThe diagnosis and medical management of advanced neuroendocrine tumors.
Kaltsas, G. A., Besser, G. M., & Grossman, A. B. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0014 · Cited by 674
Self-citationPhase II Study of Temozolomide and Thalidomide in Patients With Metastatic Neuroendocrine Tumors
Kulke, M. H., Stuart, K., Enzinger, P. C., Ryan, D. P., Clark, J. W., Muzikansky, A., Vincitore, M., Michelini, A., & Fuchs, C. S. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.6046 · Cited by 513
Pheochromocytoma: State-of-the-Art and Future Prospects
Bravo, E. L., & Tagle, R. (2003) · Endocrine Reviews · doi:10.1210/er.2002-0013 · Cited by 493
Clinical Experience Over 48 Years With Pheochromocytoma
Goldstein, R. E., O’Neill, J. A., Holcomb, G. W., Morgan, W. M., Neblett, W. W., Oates, J. A., Brown, N., Nadeau, J., Smith, B., Page, D. L., et al. (1999) · Annals of Surgery · doi:10.1097/00000658-199906000-00001 · Cited by 464
A HIF1α Regulatory Loop Links Hypoxia and Mitochondrial Signals in Pheochromocytomas
Dahia, P. L. M., Ross, K. N., Wright, M. E., Hayashida, C. Y., Santagata, S., Barontini, M., Kung, A. L., Sanso, G., Powers, J. F., Tischler, A. S., et al. (2005) · PLoS Genetics · doi:10.1371/journal.pgen.0010008 · Cited by 443
Self-citationAverbuch, S. D., Steakley, C. S., Young, R. C., Gelmann, E. P., Goldstein, D. S., Stull, R., & Keiser, H. R. (1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-109-4-267 · Cited by 427
Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings
de Jong, M., Valkema, R., Jamar, F., Kvols, L. K., Kwekkeboom, D. J., Breeman, W. A. P., Bakker, W. H., Smith, C., Pauwels, S., & Krenning, E. P. (2002) · Seminars in Nuclear Medicine · doi:10.1053/snuc.2002.31027 · Cited by 346
Current Approaches and Recommended Algorithm for the Diagnostic Localization of Pheochromocytoma
Ilias, I., & Pacak, K. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031091 · Cited by 332
Self-citationPheochromocytomas: Detection with18F DOPA Whole-Body PET—Initial Results
Hoegerle, S., Nitzsche, E., Altehoefer, C., Ghanem, N., Manz, T., Brink, I., Reincke, M., Moser, E., & Neumann, H. P. H. (2002) · Radiology · doi:10.1148/radiol.2222010622 · Cited by 325
Cited by
Plouin, P. F., Amar, L., Dekkers, O. M., Fassnacht, M., Gimenez-Roqueplo, A. P., Lenders, J. W. M., Lussey-Lepoutre, C., Steichen, O., & _, _. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0033 · Cited by 480
Ayala-Ramirez, M., Feng, L., Johnson, M. M., Ejaz, S., Habra, M. A., Rich, T., Busaidy, N., Cote, G. J., Perrier, N., Phan, A., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1946 · Cited by 428
Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma
Kimura, N., Takayanagi, R., Takizawa, N., Itagaki, E., Katabami, T., Kakoi, N., Rakugi, H., Ikeda, Y., Tanabe, A., Nigawara, T., et al. (2014) · Endocrine Related Cancer · doi:10.1530/erc-13-0494 · Cited by 393
Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas
Welander, J., Söderkvist, P., & Gimm, O. (2011) · Endocrine-Related Cancer · doi:10.1530/erc-11-0170 · Cited by 355
Koh, J.-M., Ahn, S. H., Kim, H., Kim, B.-J., Sung, T.-Y., Kim, Y. H., Hong, S. J., Song, D. E., & Lee, S. H. (2017) · PLoS ONE · doi:10.1371/journal.pone.0187398 · Cited by 114
Metadata
- Authors
- Chrisoulidou, A., Kaltsas, G., Ilias, I., & Grossman, A. B.
- Venue
- Endocrine-Related Cancer
- Publisher
- Bioscientifica
- Published
- 2007-09
- Volume
- 14
- Issue
- 3
- Pages
- 569-585
- ISSN
- 1351-0088 (ISSN-L)
- 1479-6821
- OpenAlex
- W2107966316
- Cited by
- 314
- References
- 82
- FWCI
- 19.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The diagnosis and management of malignant phaeochromocytoma and paraganglioma. https://app.cochat.ai/papers/10.1677/erc-07-0074
- The paper
- Chrisoulidou, A., Kaltsas, G., Ilias, I., & Grossman, A. B. (2007). The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocrine-Related Cancer. https://doi.org/10.1677/erc-07-0074
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.